Shares of Medtronic PLC (NYSE:MDT) ended Monday session in red amid volatile trading. The shares closed down -1.15 points or 1.31% at $86.56 with 3.73 million shares getting traded. Post opening the session at $87.28, the shares hit an intraday low of $86.29 and an intraday high of $87.46 and the price vacillated in this range throughout the day. The company has a market cap of $119.62 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) on September 26, 2016 announced U.S. Food and Drug Administration (FDA) clearance of StealthStation® Cranial Software as an aid for deep brain stimulation (DBS) lead placement. The software is fully integrated with Medtronic`s latest O-arm® Imaging System, providing clinicians with a complete procedural solution for the planning and placement of DBS leads. The announcement was made at the Congress of Neurological Surgeons (CNS) in San Diego.
With Medtronic`s DBS Therapy, a small, pacemaker-like device called a neurostimulator is implanted under the skin of the chest and sends electronic signals to an area in the brain that controls movement. Thin wires – called leads – are implanted in the brain and are connected to the neurostimulator by an extension to enable the signals to reach the source of symptoms. The new StealthStation application, which integrates pre-operative planning, intraoperative imaging and technologies to help guide surgeons during cranial procedures, is designed to improve procedural workflow and allow for DBS lead placement with a high level of accuracy.
“The new StealthStation software works seamlessly with O-arm to give me a single solution for pre-operative planning and real-time 3D imaging of the brain in the OR, and that streamlines my workflow for DBS lead placement,” said Dr. Jonathan Carlson, MD, PhD, a neurosurgeon at Providence Spokane Neuroscience Institute in Spokane, Wash. “Now I have the essential information I need in one place, giving me – and my patients – even more confidence in the procedure.”
Shares of Sophiris Bio Inc (NASDAQ:SPHS) ended Monday session in green amid volatile trading. The shares closed up +0.26 points or 8.78% at $3.22 with 3.64 million shares getting traded. Post opening the session at $2.98, the shares hit an intraday low of $2.95 and an intraday high of $3.24 and the price vacillated in this range throughout the day. The company has a market cap of $86.19 million and the numbers of outstanding shares have been calculated to be 29.12 million shares.
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companys primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.